Search

Author(s): Xiaoyan Pang [sup.1] , Fangmei Li [sup.1] , Lei Dou [sup.1] , Yichang Tian [sup.1] , Yi Zhang [sup.1] Author Affiliations: (1) grid.412636.4, 0000 0004 1757 9485, Department of [...], Patients with ovarian cancer (OC) often suffer from depressive symptoms, but the associated factors only have a small number of reports. In view of increasing attention to positive psychological resources in the field of oncology, it is necessary to explore the effects of these resources on depressive symptoms. This study explored the relations between social support and depressive symptoms, and whether resilience played a mediating role. A cross-sectional study was performed between August 2018 and March 2019. Perceived social support, resilience, and depressive symptoms were measured with the Multi-dimensional Scale of Perceived Social Support (MSPSS), the Center for Epidemiologic Studies-Depression (CES-D) scale and the Connor-Davidson Resilience Scale (CD-RISC). Hierarchical linear regression analyses were used to assess the mediating role of resilience between these variables. A total of 230 OC survivors were enrolled and finally 217 patients completed the questionnaires. The prevalence of depressive symptoms was 50.7%. After controlling for covariates, perceived social support was negatively correlated with depressive symptoms and explained 22.8% of the variance. In addition, after controlling for covariates and perceived social support, resilience was also negatively associated with depressive symptoms and explained 18.1% of the variance. Resilience could partially mediate the associations of perceived social support with depressive symptoms. Depressive symptoms in OC patients should be concerned. Perceived social support and resilience were both positive psychological resources for resisting depressive symptoms, and resilience could mediate the association between social support and depressive symptoms. It was critical to focus on social support as well as resilience in the psychosocial interventions of OC patients.

Patient-reported outcome (PRO) refers to any information about the patient's own health condition, functional status, and feelings about treatment that directly comes from the patient without interpretation by physicians, nurses or anyone else. Measuring outcomes from the patient perspective is conducive to improving the quality of medical services and treatment satisfaction. We summarized recent applications of PRO in many fields, such as drug review and approval, drug and medical equipment supervision, quality evaluation of medical services, health technology assessment, and comprehensive clinical evaluation of drugs, and reviewed the latest advances in research on PRO, such as the development of PRO instruments, the construction of a health state utility value set, the health measurement in children and adolescents, and the quality evaluation of PRO instruments. Then we put forward recommendations to further promote the studies and use of PRO in China: strengthening the development of PRO instruments applicable to China, valuing the use of PRO in clinical practice, enhancing the interdisciplinary research on PRO, broadening the profile of research on PRO, and intensifying relevant research.

In 2018, hemophilia, one of the first ones, entered into the catalogue of Rare Disease in China. However, drug accessibility and affordability have been the challenges for hemophilia patients. Therefore, a comprehensive evaluation of the cost and efficacy of hemophilia drugs is essential to push forward the appropriate application of hemophilia drugs. In the article, we have teased out the existing process of the review and approval of hemophilia drugs; have examined the procedures for the drug entry into the medical insurance policy; have systematically searched the pharmacoeconomic evaluation studies of hemophilia in published literature in both China and overseas; and have comprehensively analyzed the quality, the content of evaluation, and challenges of pharmacoeconomic studies of hemophilia in China. At last, we discuss the prospect for the future based on the following three aspects: developing a special model of hemophilia, obtaining the health utility from various sources, and establishing the threshold of willingness to pay for rare diseases, hoping to provide reference and examples to the research into pharmacoeconomic evaluation of hemophilia in China.

With the growing concerns about ecological pressure and food safety, researchers and marketers have devoted to finding effective ways to bridge the gap between consumers' high interest and weak purchasing behaviour towards green food. The unique information advantages of live streaming commerce help consumers improve their cognition of green food's benefits, evoke their concerns about health and environmental issues, and thus form positive purchasing behaviour. This study develops a conceptual framework by incorporating health consciousness and environmental awareness as mediating variables to estimate how live streaming information features impact consumers' purchasing intention and behaviour towards green food. Considering the important influences of streamer expertise and consumer attitude on purchasing behaviour, the two variables are employed in our model as moderating variables. Structural equation modelling is used to analyse data collected from 948 Chinese live streaming shoppers. The results reveal that information richness, authenticity, synchronicity, and sociability significantly enhance consumers' health consciousness and environmental awareness, and the favourable purchasing intention as well as behaviour is the result of combined impacts of health consciousness and environmental awareness. Both streamer expertise and consumer attitude play important roles in promoting consumers who intend to purchase green food to become actual buyers. The integrated model expands the empirical research of green food consumption from the perspectives of specific marketing patterns, seller and consumer characteristics, and provides a broader insight for researchers, sellers, and policy-makers to understand green food consumption and supply in emerging economies. [ABSTRACT FROM AUTHOR]

This study develops selenized potato resistant starch (P‐RS4·Se) from Enshi potato starch to enhance bioactivity. First, the resistant starch (P‐RS4) is prepared through high‐temperature citric acid esterification. Then, P‐RS4 is selenized using the nitrate‐sodium selenite method and analyzed with Scanning Electron Microscopy (SEM), Fourier Transform Infrared Spectroscopy (FTIR), X‐ray Photoelectron Spectroscopy (XPS), and Nuclear Magnetic Resonance (NMR). Optimal conditions are identified: 0.7 % HNO3, a 1:1.1 ratio of P‐RS4 to Na2SeO3, 65 °C, and 4 h. Selenization disrupts P‐RS4·Se’s microstructure, forming a Se─O─C bond with ─OH on C6. The selenized starch shows strong in vitro antioxidant effects, protecting A549 lung cancer cells from oxidative damage at 6–8 mg mL−1, supporting selenium supplementation. [ABSTRACT FROM AUTHOR]

In this study, peptides were isolated and purified from Idesia polycarpa Maxim. cake meal for the first time, with the aim of discovering peptides with excellent antioxidant properties. Peptides were isolated and purified from the cake meal using ultrafiltration and dextran gel chromatography. Fractions with significant antioxidant activity were identified by mass spectrometry (MS) and the peptides were screened and characterized using techniques, such as network pharmacology and molecular docking. The results showed that the CIPs‐I‐F2 fractions possessed excellent antioxidant activities, and a total of seven peptides were screened, with the main targets of action including serine/threonine‐protein kinase AKT (AKT1), signal transducer and activator of transcription 3 (STAT3), and matrix metalloproteinase 9 (MMP9), among which ISKPTWADF had the highest total binding energy to the target. ISKPTWADF was synthesized in vitro by solid‐phase synthesis and showed a dose‐dependent protective effect against the hydrogen peroxide (H2O2)‐induced oxidative damage model in human hepatocellular carcinoma HepG2 cells, with its main active site on the tryptophan indole ring at position 52N‐127H. [ABSTRACT FROM AUTHOR]

Objective: This study aimed to evaluate the clinical efficacy of belimumab in patients with early systemic lupus erythematosus (SLE), defined as having a disease duration of less than 6 months. Methods: We retrospectively identified patients with SLE in the early stage who received belimumab and standard of care (belimumab group) or standard of care alone (control group) since September 2020. Propensity score matching (PSM) was used to reduce potential bias. The primary endpoint was lupus low disease activity status (LLDAS) at weeks 12 and 24. The secondary endpoints were remission and the proportion of glucocorticoid dose tapering to 7.5 mg/day. The efficacy of belimumab in patients with lupus nephritis was also assessed. Results: Out of 111 eligible patients, 16 patients in the belimumab group and 31 patients in the control group were identified by 1:2 PSM. At week 24, a significantly higher proportion of individuals achieved low disease activity state (LLDAS) in the belimumab group compared to the control group (56.3% vs. 19.4%, OR = 5.357, 95% CI = 1.417 to 20.260, p = 0.013). Furthermore, more patients in the belimumab group were reduced to low‐dose glucocorticoid (≤ 7.5 mg/day) at week 24 (75.0% vs. 35.5%, OR = 5.182, 95%CI = 1.339 to 20.058, p = 0.017). Significant improvements in Patient Global Assessment scores were observed at Week 12 and 24 for those treated with belimumab compared to controls. In a subgroup analysis evaluating the efficacy of belimumab in patients with lupus nephritis, 42.9% of the seven individuals treated with belimumab achieved a complete renal response (CRR) by Week 24, and no instances of disease relapse were observed. Conclusions: In SLE patients with a disease duration of less than 6 months, belimumab treatment can promote LLDAS achievement and reduce glucocorticoid dose, leading to a better prognosis. Introducing belimumab in the early stage of SLE may be a beneficial decision. [ABSTRACT FROM AUTHOR]